MAR 2021

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1344259

Contents of this Issue


Page 117 of 118

RESTASIS® is the #1 dispensed branded eye drop 2 RESTASIS® is launched 1 Prescribed for ~7.6 million patients since launch 3 INDICATIONS AND USAGE: RESTASIS ® and RESTASIS MultiDose ® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular infl ammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-infl ammatory drugs or using punctal plugs. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: RESTASIS ® and RESTASIS MultiDose ® are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation. WARNINGS AND PRECAUTIONS POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury and contamination. USE WITH CONTACT LENSES: RESTASIS ® and RESTASIS MultiDose ® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS ® and RESTASIS MultiDose ® ophthalmic emulsion. ADVERSE REACTIONS: In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). PLEASE SEE NEXT PAGE FOR A BRIEF SUMMARY OF THE FULL PRODUCT INFORMATION. REFERENCES: 1. RESTASIS ® (cyclosporine ophthalmic emulsion) 0.05% [prescribing information]. Ir vine, CA: Allergan, Inc; 2017. 2. IQVIA, Xponent PlanTrak, Januar y 2019 - October 2019. 3. Symphony Health, PHAST Prescription Monthly, data through October 2019. © 2020 Allergan. All rights reser ved. All trademarks are the property of their respective owners. RES137633 06/20 For patients with decreased tear production presumed to be due to ocular infl ammation associated with chronic dry eye Individual results may var y. RELY ON THE 1 7 Y E A R S OF T E A R S A ND C OUN T ING

Articles in this issue

Archives of this issue

view archives of Eyeworld - MAR 2021